Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors
NCT ID: NCT03252938
Last Updated: 2026-01-23
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE1
Total Enrollment
110 participants
Study Classification
INTERVENTIONAL
Study Start Date
2017-08-15
Study Completion Date
2026-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This phase I trial aims to investigate a potential enhancement of IMP321 immune-activating effects by new routes of administration: direct injection of IMP321 into the tumor tissue; intra-peritoneal therapy; combination of chemotherapy and/or immunotherapy/targeted therapy with active immunotherapy
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies
NCT03317496
Non-small Cell Lung Cancer
Urothelial Cancer
TERMINATED
PHASE1/PHASE2
A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
NCT03782207
Urothelial Carcinoma
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
+1 more
ACTIVE_NOT_RECRUITING
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
NCT05443126
Advanced Solid Tumor
NSCLC
RECRUITING
PHASE1/PHASE2
A Study of IMP4297 in Patients With Advanced Solid Tumors
NCT03508011
Advanced Solid Tumours
Breast Cancer
Ovarian Cancer
+1 more
COMPLETED
PHASE1
A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
NCT02715531
Solid Tumor
COMPLETED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Up to now, IMP321 is solely administered by sub-cutaneous injection (e.g. on the anterior face of the thigh). In this study, we investigate whether a direct injection of IMP321 into the tumor tissue will be a useful option to improve anti-tumor immune response by placing the immune-therapeutic agent in direct vicinity of immune infiltrates in the tumor bed. This bypasses processes necessary for drug delivery to cells of solid tumors following systemic administration, like transport within vessels, transport across vasculature walls into surrounding tissues, and - in cases of peritoneal metastases - transport through the interstitial space within a tumor. For the latter case, we will also explore if an intra-peritoneal therapy represents a feasible alternative by means of delivering high drug concentrations directly to tumors located in the peritoneal cavity.
Furthermore, we will explore the possibility to extend the positive results obtained by subcutaneous injections of IMP321 in metastatic renal cell and breast carcinomas to further solid tumor entities e.g. non-small cell lung cancer (NSCLC) and urothelial carcinoma. In this part of the study, patients will be treated with the standard-of-care (SOC) chemotherapy and/or immunotherapy/targeted therapy for their tumor entity along with subcutaneous injections of IMP321.
Furthermore, we will explore the possibility to extend the positive results obtained by subcutaneous injections of IMP321 in metastatic renal cell and breast carcinomas to further solid tumor entities e.g. non-small cell lung cancer (NSCLC) and urothelial carcinoma. In this part of the study, patients will be treated with the standard-of-care (SOC) chemotherapy and/or immunotherapy/targeted therapy for their tumor entity along with subcutaneous injections of IMP321.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Solid Tumors
Peritoneal Carcinomatosis
NSCLC Adenocarcinoma
Urothelial Carcinoma
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Solid tumors
Biweekly intra-tumoral injections of escalating doses (6 mg, 12 mg, 24 mg and 30 mg) of IMP321 as a monotherapy (intratumoral injections in parenchymatous organs (e.g. liver, spleen, adrenal gland, pancreas) are not allowed)
Group Type
EXPERIMENTAL
IMP321
Intervention Type
DRUG
LAG-3Ig fusion protein, highly potent activator of antigen presenting cells
Solid tumors + peritoneal carcinomatosis
Biweekly intra-peritoneal, escalating doses of IMP321 (1 mg, 3 mg, 6 mg, 12 mg and 30 mg)
Group Type
EXPERIMENTAL
IMP321
Intervention Type
DRUG
LAG-3Ig fusion protein, highly potent activator of antigen presenting cells
Solid tumors + chemotherapy
Subcutaneous (s.c.) injections with the optimal dose of IMP321 defined in the AIPAC trial for a maximum of 24 weeks
Group Type
EXPERIMENTAL
IMP321
Intervention Type
DRUG
LAG-3Ig fusion protein, highly potent activator of antigen presenting cells
NSCLC + Avelumab/IMP321 therapy
Avelumab and IMP321 as follows:
* 800 mg avelumab every 2 weeks i.v. (for a maximum of 24 cycles \[48 weeks\])
* 6 mg (cohort 1) or 30 mg (cohort 2) IMP321 every 2 weeks s.c. (for a maximum of 12 cycles \[24 weeks\])
Group Type
EXPERIMENTAL
IMP321
Intervention Type
DRUG
LAG-3Ig fusion protein, highly potent activator of antigen presenting cells
Avelumab
Intervention Type
DRUG
Avelumab i.v.
Urothelial carcinoma + Avelumab/IMP321 combination therapy
Avelumab and IMP321 as follows:
• 800 mg avelumab every 2 weeks i.v. and 30 mg IMP321 every 2 weeks s.c. for a maximum of 24 cycles \[12 months\]
Group Type
EXPERIMENTAL
IMP321
Intervention Type
DRUG
LAG-3Ig fusion protein, highly potent activator of antigen presenting cells
Avelumab
Intervention Type
DRUG
Avelumab i.v.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
IMP321
LAG-3Ig fusion protein, highly potent activator of antigen presenting cells
Intervention Type
DRUG
Avelumab
Avelumab i.v.
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
LAG-3Ig fusion protein
efti
eftilagimod alfa
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Histologically confirmed locally advanced (not manageable with curative intent) or metastatic solid tumor Specification for Stratum C: Only patients with NSCLC adenocarcinomas, (squamous or adenosquamous not permitted) who are scheduled to receive platin + pembrolizumab + pemetrexed standard treatment (only for Stratum C) Specification for Stratum E: Including only metastatic or irresectable locally advanced urothelial carcinomas - also refer to IC#14 below (only for Stratum E)
2. Tumor is accessible for repeated injections and biopsies (only for Stratum A)
3. Peritoneal carcinomatosis (only for Stratum B)
4. Patient failed standard therapy or refused standard therapy or is intolerable towards standard therapy (Strata A, B, and D) or who receives Standard-of-Care first line treatment comprising platin + pembrolizumab + pemetrexed (only for Stratum C)
5. Patient has not received more than 4 prior lines of therapy. Neoadjuvant/adjuvant treatment is not counted unless progression occurs \<6 months after completion of the treatment. In these cases, neoadjuvant/adjuvant treatment is counted as one prior line (only for Stratum D).
Specification for Stratum C: Only patients receiving first line Standard-of-Care therapy (platin + pembrolizumab + pemetrexed; only for Stratum C) Specification for Stratum E: Refer to IC#14 below with regards to previous lines of therapy; only for Stratum E) Note exclusion criterion #7 on exclusion of defined previous cancer immunotherapy (only for Strata D)
6. Patients ≥ 18 years. Patients in reproductive age must be willing to use highly effective contraception during the study and 4 months after the end of the study (appropriate contraception is defined as combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), vasectomized partner, bilateral tubal occlusion, sexual abstinence. If an oral contraception is used, a barrier method of contraception (e.g. male condom, female condom, cervical cap, diaphragm, contraceptive sponge) has to be applied additionally.). Female patients with childbearing potential need to have a negative pregnancy test within 7 days before study start.
7. ECOG 0 or 1
8. Adequate hematological, hepatic and renal function parameters:
* ANC (absolute neutrophil count) ≥ 1,500/µL
* Leukocytes ≥ 3,000/µL
* Platelets ≥ 75,000/µL (for Stratum D: ≥ 100,000/µL)
* Serum creatinine ≤ 1.5 x upper limit of normal, or GFR ≥ 50 mL/min (not applicable for patients not eligible for platinum-based therapy in Stratum E)
* Bilirubin ≤ 1.5 - 3 x upper limit of normal (for Stratum D: ≤ 1.5 x ULN)
* AST and ALT ≤ 3 x upper limit of normal (≤ 5 x if liver metastases are present) (for Stratum D: AST and ALT ≤ 2.5 x ULN; ≤ 5 x if liver metastases are present)
* Alkaline phosphatase ≤ 6 x upper limit of normal
* Hemoglobin ≥ 9 g/dL
9. Adequate coagulation functions as defined by International Normalized Ratio (INR) ≤ 1.5, and a partial thromboplastin time (PTT) ≤ 5 seconds above the ULN (unless receiving anticoagulation therapy). Patients receiving warfarin/ phenprocoumon must be switched to low molecular weight heparin (new oral anticoagulants (NOACs) are permitted) and have achieved stable coagulation profile.
10. Patient able and willing to provide written informed consent and to comply with the study protocol and with the planned surgical procedures
11. Evidence of measurable disease as defined by RECIST v1.1 (only for Strata C, D and E) or assessable disease as defined by RECIST v1.1 (only for Stratum C)
12. Expected survival \> 3 months
13. Resolution of toxicity associated with prior or current therapy to grade \<2 (except for alopecia and transaminases in case of liver metastases)
14. Patient is eligible if one of the following settings applies (only for Stratum E):
* did suffer disease progression during/up to 3 months after pembrolizumab and enfortumab vedotin based first-line therapy and did receive at least 3 cycles of platinum based chemotherapy without displaying disease progression and are intended for Avelumab and Eftilagimod alpha as second-line maintenance therapy
* did receive at least 3 cycles of platinum based chemotherapy without displaying disease progression and are intended for Avelumab and Eftilagimod alpha as first-line maintenance therapy
2. Tumor is accessible for repeated injections and biopsies (only for Stratum A)
3. Peritoneal carcinomatosis (only for Stratum B)
4. Patient failed standard therapy or refused standard therapy or is intolerable towards standard therapy (Strata A, B, and D) or who receives Standard-of-Care first line treatment comprising platin + pembrolizumab + pemetrexed (only for Stratum C)
5. Patient has not received more than 4 prior lines of therapy. Neoadjuvant/adjuvant treatment is not counted unless progression occurs \<6 months after completion of the treatment. In these cases, neoadjuvant/adjuvant treatment is counted as one prior line (only for Stratum D).
Specification for Stratum C: Only patients receiving first line Standard-of-Care therapy (platin + pembrolizumab + pemetrexed; only for Stratum C) Specification for Stratum E: Refer to IC#14 below with regards to previous lines of therapy; only for Stratum E) Note exclusion criterion #7 on exclusion of defined previous cancer immunotherapy (only for Strata D)
6. Patients ≥ 18 years. Patients in reproductive age must be willing to use highly effective contraception during the study and 4 months after the end of the study (appropriate contraception is defined as combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), vasectomized partner, bilateral tubal occlusion, sexual abstinence. If an oral contraception is used, a barrier method of contraception (e.g. male condom, female condom, cervical cap, diaphragm, contraceptive sponge) has to be applied additionally.). Female patients with childbearing potential need to have a negative pregnancy test within 7 days before study start.
7. ECOG 0 or 1
8. Adequate hematological, hepatic and renal function parameters:
* ANC (absolute neutrophil count) ≥ 1,500/µL
* Leukocytes ≥ 3,000/µL
* Platelets ≥ 75,000/µL (for Stratum D: ≥ 100,000/µL)
* Serum creatinine ≤ 1.5 x upper limit of normal, or GFR ≥ 50 mL/min (not applicable for patients not eligible for platinum-based therapy in Stratum E)
* Bilirubin ≤ 1.5 - 3 x upper limit of normal (for Stratum D: ≤ 1.5 x ULN)
* AST and ALT ≤ 3 x upper limit of normal (≤ 5 x if liver metastases are present) (for Stratum D: AST and ALT ≤ 2.5 x ULN; ≤ 5 x if liver metastases are present)
* Alkaline phosphatase ≤ 6 x upper limit of normal
* Hemoglobin ≥ 9 g/dL
9. Adequate coagulation functions as defined by International Normalized Ratio (INR) ≤ 1.5, and a partial thromboplastin time (PTT) ≤ 5 seconds above the ULN (unless receiving anticoagulation therapy). Patients receiving warfarin/ phenprocoumon must be switched to low molecular weight heparin (new oral anticoagulants (NOACs) are permitted) and have achieved stable coagulation profile.
10. Patient able and willing to provide written informed consent and to comply with the study protocol and with the planned surgical procedures
11. Evidence of measurable disease as defined by RECIST v1.1 (only for Strata C, D and E) or assessable disease as defined by RECIST v1.1 (only for Stratum C)
12. Expected survival \> 3 months
13. Resolution of toxicity associated with prior or current therapy to grade \<2 (except for alopecia and transaminases in case of liver metastases)
14. Patient is eligible if one of the following settings applies (only for Stratum E):
* did suffer disease progression during/up to 3 months after pembrolizumab and enfortumab vedotin based first-line therapy and did receive at least 3 cycles of platinum based chemotherapy without displaying disease progression and are intended for Avelumab and Eftilagimod alpha as second-line maintenance therapy
* did receive at least 3 cycles of platinum based chemotherapy without displaying disease progression and are intended for Avelumab and Eftilagimod alpha as first-line maintenance therapy
Exclusion Criteria
1. Inability to understand the aims of the study and/or protocol procedures
2. Bleeding ulcerative tumors or tumors requiring intratumoral injections of study drug into parenchymatous organs such as, but limited to liver, spleen or pancreas (only for Stratum A)
3. Patients with contraindication versus a laparoscopy or refusing a laparoscopy (only for Stratum B)
4. Hypersensitivity towards eftilagimod alpha, avelumab (only for Strata D and E) or any ingredient of the injection/infusion solutions
5. History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
6. Any concurrent other antineoplastic treatment including irradiation, or targeted small molecule therapy, or biological cancer therapy. (only Strata A, Band D)
7. Prior PD-1/PD-L1 targeted therapy (only for Strata D).
8. Cirrhosis of the liver (Child \> Grade A), pronounced alcohol abuse with anticipated detoxification, severe pulmonary infection with considerable reduction of pulmonary function
9. Clinically significant active coronary heart disease, cardiomyopathy or congestive heart failure, NYHA III-IV (for Stratum D: ≥ NYHA II) within 6 months prior to first dose of study treatment including: myocardial infarction, severe/unstable angina, ongoing cardiac dysrhythmias of current NCI CTCAE version Grade \>2, atrial fibrillation of any grade, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident including transient ischemic attack, ventricular arrhythmias requiring medication or symptomatic pulmonary embolism
10. Cerebral or leptomeningeal metastases Note: Subjects with previously treated brain metastases may participate if they meet the following criteria: 1) are stable for at least 28 days prior to the first dose of study treatment and if all neurologic symptoms returned to baseline; 2) have no evidence of new or enlarging brain metastases; and 3) have not been using steroids for at least 7 days prior to first dose of study treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability.
11. Chronic inflammatory bowel disease
12. Active infection requiring systemic therapy at the start of study treatment or chronic infection or serious intercurrent infection within 4 weeks prior to first dose of study treatment
13. QTcF \>480 ms, family or personal history of long or short QT syndrome, Brugada syndrome or known history of QTc prolongation, or Torsade de Pointes (TdP)
14. Uncontrolled electrolyte disorders that can worsen the effects of a QTc-prolonging drug (e.g., hypocalcaemia, hypokalaemia, hypomagnesemia)
15. Positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome. Testing is not required in the absence of history.
Participants with known human immunodeficiency virus (HIV) infections are eligible if the following criteria are met:
1. If clinically indicated participants must be stable on antiretroviral therapy (ART) for at least 4 weeks and agree to adhere to ART. If not clinically indicated, consult Lead Investigator.
2. Participants with HIV infection should have no evidence of documented multidrug resistance that would prevent effective ART.
3. Have an HIV viral load of \< 400 copies/mL at Screening.
4. If prophylactic antimicrobial drugs are indicated, patient may still be considered eligible upon agreement with the Lead Investigator
16. Active hepatitis B (defined as having a positive hepatitis B surface antigen \[HBsAg\] test) or hepatitis C Note: Patients with past hepatitis B virus (HBV) infection or resolved HBV infection (defined as having a negative HBsAg test and a positive antibody to hepatitis B core antigen antibody test) are eligible. Note: Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction testing is negative for HCV ribonucleic acid (RNA). Testing is not required in the absence of history.
17. History or evidence of interstitial lung disease, active non-infectious pneumonitis or active tuberculosis
18. Active or prior autoimmune disease requiring immunosuppressive therapy that might deteriorate when receiving an immunostimulatory agent. Patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible.
19. Known history of immune-mediated colitis, pneumonitis, pulmonary fibrosis (only for Strata D and E).
20. Administration of a live, attenuated vaccine (including Covid-19 vaccination with live, attenuated vaccine) within four weeks prior to start of treatment or anticipation that such a live attenuated vaccine will be required during the remainder of the study.
21. Any condition requiring continuous systemic treatment with either corticosteroids (\>10 mg daily prednisone equivalents) or other immunosuppressive medications within 4 weeks prior to first dose of study treatment. Intranasal, inhaled or topical steroids, eye drops or local steroid injection (e.g., intra-articular injection), steroids as premedication for hypersensitivity reactions (e.g., computed tomography \[CT\] scan premedication) and physiological replacement doses of up to 10 mg daily prednisone equivalent are permitted in the absence of active autoimmune disease.
22. Treatment with systemic immunostimulatory agents (including but not limited to interferons or interleukin-2) within four weeks or five half-lives of the drug, whichever is shorter, prior to start of study treatment
23. Any previous venous thromboembolism \> National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 within the last 6 months
24. Past history of severe allergic episodes and/ or Quincke's oedema
25. Prior organ transplantation or stem cell transplantation
26. On-treatment participation in another clinical study in the period 30 days prior to start of study treatment and during the study
27. Patients in a closed institution according to an authority or court decision
28. Pregnancy or lactation
29. Planned intratumoral injections in parenchymatous organs (e.g. liver, spleen, adrenal gland, pancreas)
30. Life-threatening illness unrelated to cancer
31. History of irAEs of CTCAE Grade 4 requiring steroid treatment (only for Strata C, D and E)
32. Persisting toxicity related to prior therapy (NCI CTCAE current version Grade \> 1); however, alopecia, sensory neuropathy Grade ≤2, or other Grade ≤2 AEs not constituting a safety risk based on investigator's judgment are acceptable (only for Strata D and E)
33. Other severe acute or chronic medical conditions, psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
34. Patients with a druggable genetic alteration with an indication for targeted therapy (e.g. erdafitinib) (only for Stratum E)
2. Bleeding ulcerative tumors or tumors requiring intratumoral injections of study drug into parenchymatous organs such as, but limited to liver, spleen or pancreas (only for Stratum A)
3. Patients with contraindication versus a laparoscopy or refusing a laparoscopy (only for Stratum B)
4. Hypersensitivity towards eftilagimod alpha, avelumab (only for Strata D and E) or any ingredient of the injection/infusion solutions
5. History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
6. Any concurrent other antineoplastic treatment including irradiation, or targeted small molecule therapy, or biological cancer therapy. (only Strata A, Band D)
7. Prior PD-1/PD-L1 targeted therapy (only for Strata D).
8. Cirrhosis of the liver (Child \> Grade A), pronounced alcohol abuse with anticipated detoxification, severe pulmonary infection with considerable reduction of pulmonary function
9. Clinically significant active coronary heart disease, cardiomyopathy or congestive heart failure, NYHA III-IV (for Stratum D: ≥ NYHA II) within 6 months prior to first dose of study treatment including: myocardial infarction, severe/unstable angina, ongoing cardiac dysrhythmias of current NCI CTCAE version Grade \>2, atrial fibrillation of any grade, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident including transient ischemic attack, ventricular arrhythmias requiring medication or symptomatic pulmonary embolism
10. Cerebral or leptomeningeal metastases Note: Subjects with previously treated brain metastases may participate if they meet the following criteria: 1) are stable for at least 28 days prior to the first dose of study treatment and if all neurologic symptoms returned to baseline; 2) have no evidence of new or enlarging brain metastases; and 3) have not been using steroids for at least 7 days prior to first dose of study treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability.
11. Chronic inflammatory bowel disease
12. Active infection requiring systemic therapy at the start of study treatment or chronic infection or serious intercurrent infection within 4 weeks prior to first dose of study treatment
13. QTcF \>480 ms, family or personal history of long or short QT syndrome, Brugada syndrome or known history of QTc prolongation, or Torsade de Pointes (TdP)
14. Uncontrolled electrolyte disorders that can worsen the effects of a QTc-prolonging drug (e.g., hypocalcaemia, hypokalaemia, hypomagnesemia)
15. Positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome. Testing is not required in the absence of history.
Participants with known human immunodeficiency virus (HIV) infections are eligible if the following criteria are met:
1. If clinically indicated participants must be stable on antiretroviral therapy (ART) for at least 4 weeks and agree to adhere to ART. If not clinically indicated, consult Lead Investigator.
2. Participants with HIV infection should have no evidence of documented multidrug resistance that would prevent effective ART.
3. Have an HIV viral load of \< 400 copies/mL at Screening.
4. If prophylactic antimicrobial drugs are indicated, patient may still be considered eligible upon agreement with the Lead Investigator
16. Active hepatitis B (defined as having a positive hepatitis B surface antigen \[HBsAg\] test) or hepatitis C Note: Patients with past hepatitis B virus (HBV) infection or resolved HBV infection (defined as having a negative HBsAg test and a positive antibody to hepatitis B core antigen antibody test) are eligible. Note: Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction testing is negative for HCV ribonucleic acid (RNA). Testing is not required in the absence of history.
17. History or evidence of interstitial lung disease, active non-infectious pneumonitis or active tuberculosis
18. Active or prior autoimmune disease requiring immunosuppressive therapy that might deteriorate when receiving an immunostimulatory agent. Patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible.
19. Known history of immune-mediated colitis, pneumonitis, pulmonary fibrosis (only for Strata D and E).
20. Administration of a live, attenuated vaccine (including Covid-19 vaccination with live, attenuated vaccine) within four weeks prior to start of treatment or anticipation that such a live attenuated vaccine will be required during the remainder of the study.
21. Any condition requiring continuous systemic treatment with either corticosteroids (\>10 mg daily prednisone equivalents) or other immunosuppressive medications within 4 weeks prior to first dose of study treatment. Intranasal, inhaled or topical steroids, eye drops or local steroid injection (e.g., intra-articular injection), steroids as premedication for hypersensitivity reactions (e.g., computed tomography \[CT\] scan premedication) and physiological replacement doses of up to 10 mg daily prednisone equivalent are permitted in the absence of active autoimmune disease.
22. Treatment with systemic immunostimulatory agents (including but not limited to interferons or interleukin-2) within four weeks or five half-lives of the drug, whichever is shorter, prior to start of study treatment
23. Any previous venous thromboembolism \> National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 within the last 6 months
24. Past history of severe allergic episodes and/ or Quincke's oedema
25. Prior organ transplantation or stem cell transplantation
26. On-treatment participation in another clinical study in the period 30 days prior to start of study treatment and during the study
27. Patients in a closed institution according to an authority or court decision
28. Pregnancy or lactation
29. Planned intratumoral injections in parenchymatous organs (e.g. liver, spleen, adrenal gland, pancreas)
30. Life-threatening illness unrelated to cancer
31. History of irAEs of CTCAE Grade 4 requiring steroid treatment (only for Strata C, D and E)
32. Persisting toxicity related to prior therapy (NCI CTCAE current version Grade \> 1); however, alopecia, sensory neuropathy Grade ≤2, or other Grade ≤2 AEs not constituting a safety risk based on investigator's judgment are acceptable (only for Strata D and E)
33. Other severe acute or chronic medical conditions, psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
34. Patients with a druggable genetic alteration with an indication for targeted therapy (e.g. erdafitinib) (only for Stratum E)
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Immutep S.A.S.
INDUSTRY
Sponsor Role
collaborator
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thorsten Götze, MD
Role: PRINCIPAL_INVESTIGATOR
Institute of Clinical Cancer Research (IKF), UCT Frankfurt, Germany
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Helios Klinikum Bad Saarow
Bad Saarow, , Germany
Site Status
RECRUITING
Kliniken der Stadt Köln gGmbH, Studienzentrum der Lungenklinik, Krankenhaus Merheim
Cologne, , Germany
Site Status
RECRUITING
Universitätsklinikum Essen
Essen, , Germany
Site Status
RECRUITING
Agaplesion Markus Krankenhaus Frankfurter Diakonie Kliniken gGmbH
Frankfurt, , Germany
Site Status
RECRUITING
Krankenhaus Nordwest
Frankfurt, , Germany
Site Status
RECRUITING
Universität Gießen und Marburg GmbH
Giessen, , Germany
Site Status
RECRUITING
Hämatologisch Onkologische Praxis Eppendorf (HOPE)
Hamburg, , Germany
Site Status
RECRUITING
Marienhospital Herne, Klinik der Ruhr Universität Bochum, Klinik für Urologie
Herne, , Germany
Site Status
RECRUITING
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Mainz, , Germany
Site Status
RECRUITING
Universitätsklinikum Tübingen
Tübingen, , Germany
Site Status
RECRUITING
Universitätsklinikum Ulm, Early Clinical Trials Unit (ECTU)
Ulm, , Germany
Site Status
RECRUITING
Helios Dr. Horst Schmidt Klinikum Wiesbaden
Wiesbaden, , Germany
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Germany
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
INSIGHT
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract
NCT02928406
COMPLETED
PHASE3
Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors
NCT04780217
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
NCT07021066
RECRUITING
PHASE1
A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
NCT05155332
RECRUITING
PHASE1
Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity
NCT04273061
RECRUITING
PHASE2
Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours
NCT00475956
COMPLETED
PHASE1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
NCT05269316
RECRUITING
PHASE1/PHASE2
A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors.
NCT02579226
COMPLETED
PHASE1
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
NCT03621982
TERMINATED
PHASE1
A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors
NCT02410512
COMPLETED
PHASE1
Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
NCT02807636
COMPLETED
PHASE3
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
NCT05797168
RECRUITING
PHASE1/PHASE2
Phase I Study With AZD2171 in Patients With Advanced Solid Malignant Tumors and Liver Metastases
NCT00501605
COMPLETED
PHASE1
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
NCT03845166
ACTIVE_NOT_RECRUITING
PHASE1
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors
NCT02759666
COMPLETED
PHASE1
Immunological Variables Associated to ICI Toxicity in Cancer Patients
NCT05429866
UNKNOWN
PHASE2
Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours
NCT04999969
ACTIVE_NOT_RECRUITING
PHASE2
Phase I-II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation and Pharmacokinetics of PD-0332991 in Patients Suffering Metastatic Melanoma
NCT02202200
UNKNOWN
PHASE1/PHASE2
IMX-110 in Patients With Advanced Solid Tumors
NCT03382340
UNKNOWN
PHASE1/PHASE2
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
NCT02516241
ACTIVE_NOT_RECRUITING
PHASE3
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
NCT02723955
COMPLETED
PHASE1
A Study of ADRX-0706 in Select Advanced Solid Tumors
NCT06036121
ACTIVE_NOT_RECRUITING
PHASE1
Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors
NCT03700294
TERMINATED
PHASE1
A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549
NCT02637531
UNKNOWN
PHASE1
Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers
NCT03512340
COMPLETED
PHASE1